Seelos Therapeutics (DB:NXE0) - Prezzo delle azioni, notizie e analisi

NXE0 Panoramica delle azioni

A clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders.

Informazioni sull'azienda

NXE0 analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	0/6

Premi

Analisi del rischio

Le azioni sono altamente illiquide

Gli utili sono diminuiti del 13.1% all'anno negli ultimi 5 anni

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

Non ha una capitalizzazione di mercato significativa ( €727K )

+ 2 più rischi

Seelos Therapeutics, Inc. Concorrenti

MPH Health Care

DB:93M1

€101.0m

SciSparc

NasdaqCM:SPRC

US$758.2k

Biofrontera

XTRA:B8FK

€17.5m

Resonate Blends

OTCPK:KOAN

US$642.6k

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Seelos Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$2.00
Massimo di 52 settimane	US$288.96
Minimo di 52 settimane	US$2.00
Beta	1.89
1Variazione di 1 mese	0%
Variazione a 3 mesi	n/a
Variazione di 1 anno	-99.31%
3Variazione a 3 anni	-99.50%
Variazione a 5 anni	-99.43%
Variazione dall'IPO	-99.76%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	NXE0	DE Pharmaceuticals	DE Mercato
7D	0%	-2.4%	-2.2%
1Y	-99.3%	-13.3%	13.3%

Ritorno vs Industria: NXE0 ha avuto una performance inferiore rispetto al German Pharmaceuticals che ha registrato un rendimento -13.3 % nell'ultimo anno.

Rendimento vs Mercato: NXE0 ha avuto una performance inferiore al mercato German che ha registrato un rendimento 13.3 % nell'ultimo anno.

Volatilità dei prezzi

Is NXE0's price volatile compared to industry and market?
NXE0 volatility
NXE0 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.8%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.2%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: NXE0 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di NXE0 nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2016	10	Raj Mehra	seelostherapeutics.com

Seelos Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Seelos Therapeutics con la sua capitalizzazione di mercato?
NXE0 statistiche fondamentali
Capitalizzazione di mercato	€665.26k
Guadagni(TTM)	-€24.82m
Ricavi(TTM)	€1.81m

0.4x

Rapporto P/S

0.0x

Rapporto P/E

NXE0 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
NXE0 Conto economico (TTM)
Ricavi	US$1.97m
Costo del fatturato	US$27.97m
Profitto lordo	-US$26.00m
Altre spese	US$1.12m
Guadagni	-US$27.11m

Ultimi guadagni dichiarati

Mar 31, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-9.48
Margine lordo	-1,317.12%
Margine di profitto netto	-1,373.61%
Rapporto debito/patrimonio netto	-39.5%

Come si è comportato NXE0 nel lungo periodo?

Vedi performance storica e confronto

NXE0 Panoramica delle azioni

Premi

Analisi del rischio

Seelos Therapeutics, Inc. Concorrenti

DB:93M1

€101.0m

NasdaqCM:SPRC

US$758.2k

XTRA:B8FK

€17.5m

OTCPK:KOAN

US$642.6k

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index

Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

Seelos Therapeutics, Inc., Annual General Meeting, Sep 27, 2024

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.136948 million.

Recent updates

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index

Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index

Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

Seelos Therapeutics, Inc., Annual General Meeting, Sep 27, 2024

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $1.136948 million.

Seelos Therapeutics Announces 1-for-8 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement of $1.00 Per Share of Common Stock for Continued Listing on the Nasdaq Capital Market

Nasdaq to Delist Common Stock of Seelos Therapeutics

Seelos Therapeutics, Inc. Announces Appointment of Richard Pascoe as Chairman of the Board of Directors

Seelos Therapeutics, Inc. Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005 (IV Trehalose)

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $4.000001 million.

Seelos Therapeutics, Inc. Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002

Founder recently bought €92k worth of stock

New major risk - Market cap size

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering.

Seelos Therapeutics, Inc. has filed a Follow-on Equity Offering.

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Seelos Therapeutics Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

Seelos Therapeutics Receives Non-Compliance Notice From Nasdaq

Seelos Therapeutics, Inc. Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide

Seelos Therapeutics, Inc. Announces the Close of Enrollment of Its Registration Directed Study of Sls-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (Asib) in Adults with Major Depressive Disorder (MDD)

Listing Qualifications Staff of Nasdaq Provides Notice to Seelos Therapeutics for Not Regain Compliance with Rule 5550(a)(2) and Not Eligible for Second 180 Calendar Day Compliance Period

No longer forecast to breakeven

Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos Therapeutics Doses First Patients in an Ethnobridging Study with Sls-002 (Intranasal Racemic Ketamine)

Seelos Therapeutics, Inc. Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease

Seelos Therapeutics Receives Written Notice of Non-Compliance from Nasdaq

Seelos Therapeutics Doses First Patient in A Registrational Phase II/III Study of SLS-005 in Spinocerebellar Ataxia

Seelos Therapeutics Inc. Receives A Research and Development Grant from the Michael J. Fox Foundation for Parkinson's Research for SLS-004

Seelos Therapeutics, Inc. Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in Vitro Gene Therapy Study

Seelos Therapeutics, Inc. Receives Notice of Allowance in U.S. for an Additional Patent for SLS-007

Seelos Therapeutics Receives Written Notice from The Nasdaq Stock Market LLC Regarding Minimum Bid Price Requirement

Seelos Therapeutics, Inc., Annual General Meeting, May 20, 2022

Founder recently bought €51k worth of stock

Seelos Therapeutics, Inc. Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

Seelos Therapeutics, Inc. announced that it has received $20 million in funding from The Lind Partners, LLC

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Director Judith Dunn has left the company

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $60.000004 million.

Seelos Therapeutics, Inc. Announces Positive Data from the Open-Label Study of SLS-002

Seelos Therapeutics Announces Completion of Open-Label Patient Enrollment of Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002 (Intranasal Racemic Ketamine Program)

New 90-day high: €3.20

New 90-day high: €1.60

Seelos Therapeutics, Inc. Announces Dosing of the First Patients in its Registrational Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior

Seelos Therapeutics Regains Compliance with Minimum Bid Price Requirement

New 90-day high: €1.33

Seelos Therapeutics, Inc. announced that it has received $10 million in funding from The Lind Partners, LLC

New 90-day high: €0.93

Revenue in line with expectations

Seelos Therapeutics, Inc. Announces Sponsored Research Agreement with Duke University for Gene Therapy Studies of SLS-004 in Parkinson's Disease

Seelos Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.00335 million.

New 90-day low - €0.56

New 90-day low - €0.70

Seelos Therapeutics, Inc.(NasdaqCM:SEEL) dropped from Russell Microcap Value Index